bioAffinity Technologies, Inc. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
bioAffinity Technologies reported Q3 2026 CyPath Lung sales increased >100% versus Q3 2025 (1,620 tests vs. 775 tests). Ordering physicians grew 89% YoY; repeat physicians from 2025 increased usage 48%. Company signed distribution agreement with Veteran-Owned AvMEDICAL to expand VA/government healthcare access.
Why this rating
Strong revenue growth and physician adoption on small revenue base (~$22.6M market cap) are meaningful. Unspecified absolute dollar amounts limit precision, but test volume doubling and 89% physician growth suggest trajectory shift. AvMEDICAL deal upside unknown.
Tradability signal
NO TRADE
No trade: price $0.34 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.34 | +10 min · unknown $0.50 ▲ 47.02% | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.